tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GANX Stock Latest News

Gain Therapeutics to present preclinical data on GT-02287 at Neuroscience 2024
The FlyGain Therapeutics to present preclinical data on GT-02287 at Neuroscience 2024
17h ago
GANX
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
PremiumPress Releases
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
18h ago
GANX
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
PremiumPress Releases
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
22d ago
GANX
Gain Therapeutics announces reuslts from Phase 1 study of GT-02287
PremiumThe Fly
Gain Therapeutics announces reuslts from Phase 1 study of GT-02287
22d ago
GANX
Gain Therapeutics assumed with an Outperform at Oppenheimer
PremiumThe Fly
Gain Therapeutics assumed with an Outperform at Oppenheimer
1M ago
GANX
Gain Therapeutics reports Q2 EPS (42c), consensus (20c)
PremiumThe FlyGain Therapeutics reports Q2 EPS (42c), consensus (20c)
1M ago
GANX
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Premium
Press Releases
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
1M ago
GANX
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
Premium
Company Announcements
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
2M ago
8K
GANX
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
PremiumPress Releases
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
2M ago
GANX
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
PremiumThe Fly
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
2M ago
GANX
Gain Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
PremiumThe Fly
Gain Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
3M ago
GANX
Gain Therapeutics Leadership Changes and Executive Compensation
PremiumCompany Announcements
Gain Therapeutics Leadership Changes and Executive Compensation
3M ago
8K
GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
PremiumPress ReleasesGain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
3M ago
GANX
Gain Therapeutics CEO Matthias Alder departs, Gene Mack named interim CEO
Premium
The Fly
Gain Therapeutics CEO Matthias Alder departs, Gene Mack named interim CEO
3M ago
GANX
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Premium
Press Releases
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
3M ago
GANX
Gain Therapeutics announces presentation of poster at FENS forum 2024
PremiumThe Fly
Gain Therapeutics announces presentation of poster at FENS forum 2024
3M ago
GANX
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
PremiumPress Releases
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
3M ago
GANX
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
PremiumPress Releases
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
3M ago
GANX
Gain Therapeutics Launches Public Offering and Warrants Deal
PremiumCompany Announcements
Gain Therapeutics Launches Public Offering and Warrants Deal
3M ago
8K
GANX
Gain Therapeutics 7.12M share Spot Secondary priced at $1.35
PremiumThe FlyGain Therapeutics 7.12M share Spot Secondary priced at $1.35
3M ago
GANX
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
Premium
Press Releases
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
3M ago
GANX
Gain Therapeutics Announces Proposed Public Offering
Premium
Press Releases
Gain Therapeutics Announces Proposed Public Offering
3M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >